• Most Popular
  • Most Shared

According to New Study, India's Nutraceuticals Market Should Achieve a Market Size...

Thu Feb 28, 2008 10:30pm EST
According to New Study, India's Nutraceuticals Market Should Achieve a Market Size of INR27 Billion in 2009

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c84393) has announced the
addition of Clinical Trails in India to their offering.

   Along with the growing healthcare industry in India there is an
emerging trend in 'Fast Moving Healthcare Goods (FMHG)' in India;
worldwide known as Nutraceuticals, which are by definition,
ingredients with human health benefits beyond basic nutrition.

   According to Cygnus estimates, nutraceuticals market in 2007 was
INR18.75 billion and expected to grow at 20% CAGR to achieve a market
size of INR27 billion in 2009. Global nutraceuticals market is
estimated at USD120 billion in 2007 growing at 7% (CAGR).The US has
been the major market for nutraceuticals with India and China becoming
fastest growing markets. Nutraceuticals are gaining acceptance for
their ability to address several diseases. Vitamins, Minerals and
Nutrients constitute about 85% of the market while antioxidants and
anti-agents account for 10% other segments such as herbal extracts
occupy 5% of the market, globally. Cygnus has considered
nutraceuticals along with functional foods to estimate the total
market of nutraceuticals, both global and Indian market.

   The report aims at recent trend in the industry, global market and
its trend, estimates of the future market, growth drivers, critical
success factors, issues and challenges, regulatory environment,
profiles of major players and their products offering. The report has
eight chapters and figures and tables showing major industry data. The
report will be useful for industry research analysts, Pharma and other
food manufacturing companies, financial institutes, and research
institutes interested in broad overview of the industry, market its
trend and future trend.

   Companies Mentioned:

   Clinigene

   Dr Reddy's Laboratories Limited

   GlaxoSmithKline

   Lupin Limited

   Novartis

   Pfizer Limited

   Ranbaxy Laboratories Limited

   Torrent Pharmaceuticals Limited

   Vimta Labs Limited

   Cadila healthcare Unlisted in BSE / NSE

   Asian Clinical Trials Limited

   BioServe Clinical Research Pvt. Ltd

   Clininvent Research Pvt. Ltd.,

   ClinTec International

   Eli Lilly and Company (India) Pvt. Ltd

   iGATE Clinical Research International

   Intas Pharmaceuticals

   Johnson & Johnson, India

   Lambda Therapeutic Research Ltd

   Lotus Labs Pvt. Ltd.

   Matrix Laboratories Ltd.

   Merck Limited

   Novo Nordisk India Private Ltd.

   Pharmanet

   Quintiles Research (India) Private Limited

   Reliance Clinical Research Services

   Roche India Ltd.,

   Sanofi-Aventis (Aventis Pharma Limited)

   Siro Clinpharm Pvt Ltd.

   SRL Ranbaxy

   Sristek

   Synchron Research Pvt. Ltd.

   For more information visit
http://www.researchandmarkets.com/reports/c84393

Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008



More from Reuters

Photo

Tech solutions to climate change

Experts say there is no single answer to solving global warming, but a handful of technologies could be promising. Check out some of the candidates and join the debate.  Full Article 

    Onlookers gather outside the historic Federal Hall where U.S. President Barack Obama is speaking in the heart of Wall Street in New York September 14, 2009. REUTERS/Larry Downing

    One step closer to reform

    The House of Representatives approved the biggest changes in financial regulation since the Great Depression, marking a win for the Obama administration and congressional Democrats.  Full Article 

     The share price index DAX board is seen in front of an emergency exit sign at Frankfurt's stock exchange, October 8, 2008. REUTERS/Kai Pfaffenbach

    "Deflation is with us"

    Fear of the market abyss has faded for investors, but another fear is lurking on the horizon, if not already here.  Full Article